Arovella Therapeutics Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: -0.090x

Arovella Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) has a cash flow conversion efficiency ratio of -0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.71 Million ≈ $-1.21 Million USD) by net assets (AU$18.92 Million ≈ $13.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Arovella Therapeutics Ltd (2013–2025)

Cash flow conversion efficiency of Arovella Therapeutics Ltd from 2013 to 2025. This chart illustrates how Arovella Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Arovella Therapeutics Ltd stock price for real-time trading data and today's change.

Arovella Therapeutics Ltd Cash Flow Conversion Ratio Explained

Arovella Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Arovella Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Arovella Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see Arovella Therapeutics Ltd market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Apollo Minerals Ltd AU:AON	-0.137x
Altustfi WAR:ALI	0.034x
Dimension Computer Technology Co Ltd TWO:6140	0.186x
Elastron S.A. - Steel Service Centers AT:ELSTR	-0.043x
Greatland Resources Limited LSE:GGP	0.460x
Unifosa TWO:8277	0.064x
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA F:MUT3	0.033x
Entertainment Network (India) Limited NSE:ENIL	-0.015x

Annual Cash Flow Conversion Efficiency for Arovella Therapeutics Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Arovella Therapeutics Ltd from 2013 to 2025. Review ALA FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$20.08 Million ≈ $14.21 Million	AU$-6.93 Million ≈ $-4.90 Million	-0.345x	+43.94%
2024-06-30	AU$11.23 Million ≈ $7.94 Million	AU$-6.91 Million ≈ $-4.89 Million	-0.616x	+63.62%
2023-06-30	AU$3.78 Million ≈ $2.67 Million	AU$-6.40 Million ≈ $-4.53 Million	-1.692x	-105.66%
2022-06-30	AU$7.62 Million ≈ $5.39 Million	AU$-6.27 Million ≈ $-4.44 Million	-0.823x	-108.53%
2021-06-30	AU$8.98 Million ≈ $6.36 Million	AU$-3.54 Million ≈ $-2.51 Million	-0.395x	+43.41%
2020-06-30	AU$4.14 Million ≈ $2.93 Million	AU$-2.88 Million ≈ $-2.04 Million	-0.697x	-290.58%
2019-06-30	AU$13.98 Million ≈ $9.89 Million	AU$-2.50 Million ≈ $-1.77 Million	-0.179x	+19.67%
2018-06-30	AU$11.46 Million ≈ $8.11 Million	AU$-2.55 Million ≈ $-1.80 Million	-0.222x	-338.46%
2017-06-30	AU$16.85 Million ≈ $11.92 Million	AU$-854.22K ≈ $-604.42K	-0.051x	+53.29%
2016-06-30	AU$16.61 Million ≈ $11.75 Million	AU$-1.80 Million ≈ $-1.28 Million	-0.109x	+33.60%
2015-06-30	AU$19.30 Million ≈ $13.66 Million	AU$-3.15 Million ≈ $-2.23 Million	-0.163x	+0.04%
2014-06-30	AU$15.99 Million ≈ $11.32 Million	AU$-2.61 Million ≈ $-1.85 Million	-0.164x	+32.03%
2013-06-30	AU$6.69 Million ≈ $4.73 Million	AU$-1.61 Million ≈ $-1.14 Million	-0.241x	--

About Arovella Therapeutics Ltd

AU:ALA Australia Biotechnology

Market Cap

$42.76 Million

AU$60.44 Million AUD

Market Cap Rank

#22292 Global

#779 in Australia

Share Price

AU$0.05

Change (1 day)

+0.00%

52-Week Range

AU$0.05 - AU$0.10

All Time High

AU$0.57